Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:09:03 EDT Wed 26 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:REGN - REGENERON PHARMACEUTICALS INC - https://www.regeneron.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
REGN - Q0.1620.00·637.000.5634.14-26.86-4.1852.7544,96124,803662.45  662.5699  633.101,211.1999  642.0019:59:2316:0515 min RT 2¢

Recent Trades - Last 10 of 24803
Time ETExPriceChangeVolume
19:59:23Q635.55-25.451
19:57:38Q635.65-25.351
19:54:00Q635.65-25.3530
19:51:13Q635.65-25.358
19:50:00Q635.65-25.358
19:49:49Q635.65-25.358
19:47:13Q635.00-26.004
19:44:58Q635.65-25.358
19:44:05Q635.65-25.358
19:43:45Q635.65-25.358

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-03-25 16:05U:REGNNews ReleaseRegeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
2025-03-11 22:50U:REGNNews ReleaseRegeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
2025-03-11 21:32U:REGNNews ReleaseRegeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
2025-03-08 13:00U:REGNNews ReleaseDupixent(TM) (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
2025-02-28 07:00U:REGNNews ReleaseLinvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
2025-02-26 07:00U:REGNNews ReleaseOdronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
2025-02-24 15:00U:REGNNews ReleaseLatest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial
2025-02-18 00:59U:REGNNews ReleaseDupixent(TM) (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
2025-02-11 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentations
2025-02-11 07:01U:REGNNews ReleaseLinvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
2025-02-08 17:40U:REGNNews ReleaseEYLEA HD(TM) (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
2025-02-08 15:55U:REGNNews ReleaseThree-Year Results for EYLEA HD(TM) (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
2025-02-04 06:30U:REGNNews ReleaseRegeneron Reports Fourth Quarter and Full Year 2024 Financial and Operating Results; Initiates Quarterly Dividend and Increases Total Share Repurchase Capacity to ~$4.5 Billion
2025-01-23 12:02U:REGNNews ReleaseAmerica's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
2025-01-21 14:35U:REGNNews ReleaseREGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
2025-01-16 05:45U:REGNNews ReleaseThe Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
2025-01-13 06:30U:REGNNews ReleaseRegeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
2025-01-13 06:16U:REGNNews ReleaseAdjuvant Libtayo(TM) (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
2025-01-13 06:05U:REGNNews ReleaseRegeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery